Buy
Sell
Share Name Share Symbol Market Type Share ISIN Share Description
Byotrol Plc LSE:BYOT London Ordinary Share GB00B0999995 ORDS 0.25P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.0% 6.30 6.20 6.40 6.35 6.30 6.30 146,919 08:00:28
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Chemicals 6.1 -0.0 0.1 78.8 29

Byotrol Share Discussion Threads

Showing 9276 to 9297 of 11750 messages
Chat Pages: Latest  374  373  372  371  370  369  368  367  366  365  364  363  Older
DateSubjectAuthorDiscuss
01/5/2020
14:22
The publicity around MAP -1 won't help byot.
brownson
01/5/2020
13:24
I would not engage with someone who persists in trying to damage a company that is working flat out to help people. He clearly has an agenda and no respect for those people at byot who are working at this time.
slicethepie
01/5/2020
13:17
finnCap implying revenues of c.£9m as there has been a fundamental shift in disinfection You know how this works STT and Dan - it's not rear view mirror stuff but forward looking that matters
techair
01/5/2020
12:51
Dan, Absolutely, they are a serial disappointer and the TU showed it, as expected.. The BoD stated in March that they were expecting fy EBIDTA to exceed expectations whereas in fact, fy EBITDA didn't.... Last year's accounts were late resulting in the shares being suspended and their accounts not being qualified. They have now changed auditors!!! That questions the BoD credibility... The point is the lth gang knew about the questionable past and that they had a history of disappointing, losing contracts etc, yet the gang pumped/dumped it so they could sell/reduce their holdings... It's nice to have an investment decision proven right so conclusively BY EVENTS.
sikhthetech
01/5/2020
12:34
A.Fewbob TERN need adding to any Pandemic watch list as their 4 investee companies ignore the testing/avoidance scenarios,thus serving to reduce sector risk. (++ they are about to fly at an even faster rate.)
mudbath
01/5/2020
06:45
Look at the history of the other covid stocks I mentioned!!!! None have performed well until now.
a.fewbob
30/4/2020
23:14
The business had nearly £6m of revenue forecast back in 2009. 11 years later.... https://www.edisoninvestmentresearch.com/?ACT=18&ID=1421
dan_the_epic
30/4/2020
21:48
"Sikh isn't wrong" Thats a first
riddlerone
30/4/2020
21:40
Sikh isn't wrong as this is a serial disappointer share this and not fond of management. Long term share price chart says it all. I am yet to be convinced this will fulfil all that people have baked in this year
dan_the_epic
30/4/2020
20:00
And Brownson, Just to update you, Synairgen up 16% today. So now 3 out my four Pandemic shares are in profit. Two of them massively so. Just BYOT to play catch up!
a.fewbob
30/4/2020
13:29
A.Fewbob, "obviously negotiating licence deals doesn’t happen overnight." The initial patent was around 25yrs ago. They IPO was around 15yrs, so not overnight!! Whatever happened to all those deals following the Swine flu pandanmic.. A DECADE AGO, so not overnight!! "The significant increase in sales is in part due to the concern regarding swine flu; however it can also be attributed to a greater appreciation of the qualities, efficacy and broad applications of Byotrol. " "We remain confident of the prospects for Byotrol " Distributors & Parners " Healthcare through our relationship with Synergy Health plc in Europe and through distributors in the US * Food and beverage, both through distributors and direct sales * Consumer products through our joint venture, Byotrol Consumer Products Ltd. " https://uk.advfn.com/stock-market/london/byotrol-BYOT/share-news/Interim-Results/40388101 yet, despite the huge increase in sales, they still had placings after Swine Flu outbreak... 29-08-15 .. £1.4m 25-06-14 .. £1.25m 25-06-13 .. £0.50m 21-10-11 .. £2.46m It's nice to have an investment decision proven right so conclusively BY EVENTS.
sikhthetech
30/4/2020
13:11
Melody999 Byot have already stated that they expect the high levels of orders to ease... "Whilst we EXPECT the current very high levels of demand to EASE at some stage over the course of FYE 2021" https://byotrolplc.com/wp-content/uploads/2020/04/2020-04-24-TU-FINAL-pdf.pdf
sikhthetech
30/4/2020
13:10
Melody999 "the market will start look forward again:." It's not good when a company presented with a huge opportunity is unable to even meet their expectations without Covid-19. It's even more questionable that in the Covid TU, published only a month ago, they stated that they will exceed guidance in the interims... They never published any expectation figures in the interims. Their house broker did, yet they failed to meet those expectations, despite the huge sales due to covid19. "Byotrol's results to 31 March 2020 are now expected to exceed the guidance given at the time of our interim results, where we confirmed our expectations of positive EBITDA for the full year. " https://uk.advfn.com/stock-market/london/byotrol-BYOT/share-news/Byotrol-PLC-Trading-Update/82053342
sikhthetech
30/4/2020
00:49
Not at all, Bought Nivacyt, made a packet Bought Avacta, made a packet Also hold Synairgen which hasn’t risen. Need trial results, could go either way. BYOT has been given a nice boost of momentum but obviously negotiating licence deals doesn’t happen overnight. These will do exceptionally well over the next six months.
a.fewbob
29/4/2020
11:45
A.Fewbobless
brownson
29/4/2020
10:13
Just added more on the dip today
tonytyke
29/4/2020
10:04
May have missed expectations but that is all looking backwards and the market will start look forward again:. From the 270420 TU: Byotrol has been positioning for such trends for many years and expects them to favour technologies like ours, presenting exceptional growth opportunities for the Group. Now expect FY2021 to be one of significant growth in both revenue and EBITDA. And the 230320 TU: Firm orders currently sit at £1.7m for deliveries to end of June, with many more orders still being processed. Historically our order book at this time of year has been around £0.35m
melody9999
29/4/2020
09:36
Joined the party with 40,000 @ 5.2p Registered as a sell, buying at the bid on LSE Fall now reversing
fizzypop
29/4/2020
09:28
3.5p. Are you taking the peez?
loafofbread
29/4/2020
09:22
Weak support at 5.00p else back down to 3.50p.
eeza
29/4/2020
08:55
The rocks being thrown at byotrol’s FY20 performance, in terms of failing to meet broker forecasts and unimpressive year-on-year comparisons, perhaps show why it would be good to get some more granularity into the reporting, either from byotrol itself, or through broker notes. Year-on-year comparisons are complicated by the fact that Medimark was only in for 7 months or so of FY19 but also by the big Solvay contribution booked in FY19. A starting point is perhaps to break down the performance between Medimark and the pre-Medimark business. Medimark is a growing product-sales-based business which is profitable, whereas pre-Medimark, byotrol performance was significantly influenced by individual deals such as the Solvay licensing deal, without which it would have been loss-making (adj EBITDA). In FY19 in particular, I think there was a £1.9m revenue contribution booked from the Solvay deal. Medimark. £2.7m revenue FY18 (year-ending 31/3/2018) £3.0m revenue FY19 (full year, not just post-acquisition) Byotrol (excl Medimark contribution in FY19) £1.8m revenue FY18 (as re-stated in FY19 accounts) £3.9m revenue FY19 (incl £1.9m Solvay) Without the Solvay deal, I think pro-forma Byotrol + Medimark (i.e. including 12 months of Medimark) would have been about £5.0m revenue in FY19. So £6.0m FY20, if it is all from underlying product sales, shows healthy underlying growth, but we do not yet know how much, if any, contribution there is in the FY20 number from “up-front̶1; licensing deals (i.e. non-recurring revenue not related to actual product sales). (Errors excepted)
1gw
28/4/2020
19:38
A.Fewbob, "It’s the forward looking statement that counts." Agree, the forward looking statement is what counts... They state that they have a strong order book for the FIRST QUARTER, ie next TWO months, ending June. Rest is EXPECT, PRESENTING or Jam tomorrow and STILL ASSESSING MANY (not significant) orders. Where's the visibility past next 2 months, Qtr 1 end June.??? Surely they would know if they had strong order book for Q2 as well. Last year, the fy results were published Mid-Oct, although due Sept, so it could be still 5-6 months before there's any more clarity . "We entered the new financial year with a strong order book exceeding £2m and expect to generate record sales from products (i.e. excluding licenses, royalties and technical development deals) in the first quarter of the year." "There are also many additional orders STILL being assessed for deliverability against the supply chain constraints being experienced across our whole industry sector." "Whilst we EXPECT the current very high levels of demand to EASE at some stage over the course of FYE 2021" https://byotrolplc.com/wp-content/uploads/2020/04/2020-04-24-TU-FINAL-pdf.pdf
sikhthetech
Chat Pages: Latest  374  373  372  371  370  369  368  367  366  365  364  363  Older
ADVFN Advertorial
Your Recent History
LSE
BYOT
Byotrol
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20210612 16:40:52